WuXi Biologics Boosts Complex Biologics Pipeline
WuXi Biologics partners with Sinorda on bispecific antibodies for autoimmune diseases and HanchorBio on fusion proteins for oncology and immunology.
WuXi Biologics
Merck & Co. Acquires Vaccine Site in Ireland from WuXi
As part of its long-term plans in the country, US drugmaker Merck & Co., operating as MSD outside of North America, has acquired WuXi Biologics’ site in Dundalk, Ireland, for about $500 million. The deal was announced through Ireland’s Foreign Direct Investment Agency (IDA) and MSD’s Ireland unit.
WuXi Biologics Expands Production Capacity at Massachusetts Site
China-headquartered contract research, development and manufacturing organization (CRDMO) WuXi Biologics plans to increase the manufacturing capacity of its US facility in Worcester, Massachusetts to 36,000 l, 12,000 l more than the originally planned 24,000 l.
Wuxi Biologics Plans Spin-off and Separate Listing of Wuxi XDC
Chinese contract research, development, and manufacturing organization (CRDMO) Wuxi Biologics announced the planned spin-off and separate listing of its subsidiary WuXi XDC on the Hong Kong Stock Exchange. Upon completion of the proposed listing, Wuxi XDC will remain a consolidated subsidiary.
Ramping Up Biomanufacturing Capacity
Biomanufacturing for both traditional biologics and new modalities, such as cell and gene therapies, continues to be an active area of investment for CDMOs/CMOS. Some of the major investments by the larger CMDOs/CMOs are outlined in this article.
